SCHEMBL623033

SCHEMBL623033

O=C(O)c1c(Br)csc1Br

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
GPR35 Q9HC97 7/20 0.39
TTR P02766 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
GSK3B P49841 2/20 0.34
ALAD P13716 1/20 0.34
DAO P14920 4/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28196417 0.81 TSHR (0.65) TSHRGPR35CES2CES1GSK3B
SCHEMBL17398273 0.79 TSHR (0.47) TSHRGPR35DAO
SCHEMBL4036013 0.79 TSHR (0.47) TSHRGPR35CES2CES1ALAD
SCHEMBL16414224 0.78 TSHR (0.40) TSHRGPR35CES2CES1GSK3B
SCHEMBL1973884 0.78 GPR35 (0.47) TSHRGPR35GSK3B
SCHEMBL28291543 0.76 GPR35 (0.46) TSHRGPR35CES2CES1ALAD
SCHEMBL19260334 0.76 PRKCZ (0.40) TSHRGPR35TTRCES2CES1
SCHEMBL2001851 0.76 TSHR (0.44) TSHRGPR35CES2CES1DAO
SCHEMBL25238207 0.73 GPR35 (0.43) TSHRGPR35GSK3B
SCHEMBL14911645 0.73 TSHR (0.36) TSHRGPR35TTRCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150175563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175593-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-8796271-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-8796268-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
EP-2603214-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2013-06-19 EP disclosed
US-20120178723-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-20120172345-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-05 US disclosed
WO-2012021696-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
EP-2254727-A2 METHOD OF THERMOCLEAVING A POLYMER LAYER The Technical University of Denmark (DTU) (DK) 2010-12-01 EP disclosed
WO-2009103706-A2 METHOD OF THERMOCLEAVING A POLYMER LAYER THE TECHNICAL UNIVERSITY OF DENMARK (DK) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172345-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 TSHR 1990/4885GPR35 1760/4885TTR 4356/4885
US-20150175563-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 TSHR 1990/4885GPR35 1760/4885TTR 4356/4885
US-20120178723-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 TSHR 1964/4885GPR35 1993/4885TTR 4008/4885
US-20150175593-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 TSHR 1964/4885GPR35 1993/4885TTR 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.